Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601)
Anticancer Research · 2023
DOI: 10.21873/anticanres.16771 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Anticancer Research, 2023. Verfasst von Sho Sato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan.
- Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan; s0714@yokohama-cu.ac.jp.
- Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Zitieren
APA
Sato, S., Kunisaki, C., Tamura, Y., Yago, A., Kasahara, K., Sato, T., Kondo, H., Kosaka, T., Akiyama, H., & Endo, I. (2023). Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601). Anticancer Research. https://doi.org/10.21873/anticanres.16771
Vancouver
Sato S, Kunisaki C, Tamura Y, Yago A, Kasahara K, Sato T, et al. Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601). Anticancer Research. 2023. doi:10.21873/anticanres.16771
BibTeX
@article{Sato2023,
author = {Sato, Sho and Kunisaki, Chikara and Tamura, Yuko and Yago, Akikazu and Kasahara, Kohei and Sato, Tsutomu and Kondo, Hiroki and Kosaka, Takashi and Akiyama, Hirotoshi and Endo, Itaru},
title = {Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601)},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16771}
}
EUVIMED